# US 2021/0060055 A1 · Methods and compositions for treating cancers using antisense

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060055 A1
- Document ID: US20210060055A1
- Status: Published application
- Kind: A1
- Application number: 17/020,879
- Filed: 2020-09-15
- Published: 2021-03-04
- Earliest claimed: 2017-03-09
- Assignees: Thomas Jefferson University
- Applicants: Thomas Jefferson University
- Inventors: David W. Andrews; Douglas C. Hooper
- Web page: https://patentgrep.com/patent/US20210060055A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 39/001103: {Receptors for growth factors}
- A61P 35/00: Antineoplastic agents
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/5152: {Tumor cells}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2310/11: Antisense
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

## Claims

### Claim 1

A method of vaccinating a subject having a brain cancer comprising:
(i) obtaining morselized tumor tissue from the subject;
(ii) collecting the moreslized tissue in a sterile trap;
(iii) harvesting adherent cells from the moreslized tissue;
(iv) encapsulating the harvested cells in a biodiffusion chamber along with insulin-like growth factor receptor-1 antisense oligodeoxynucleotide (IGF-1R AS ODN) having the sequence of SEQ ID NO:1; wherein the chamber contains about 750,000 to about 1,250,000 tumor cells;
(v) irradiating the chamber, and
(vi) implanting the chamber in the subject,
wherein an immune response against the brain cancer is obtained.

### Claim 2 (depends on 1)

The method of claim 1 comprising the step of treating the adherent cells with IGF-1R AS ODN for up to 18 hours prior to encapsulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is vaccinated with 20 chambers for about 48 hours.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ratio of tumor cells to AS ODN in the chamber is in a range from about 3.75×105 cells:1 μg AS ODN to about 6.25×105 cells: 1 μg AS ODN.

### Claim 5 (depends on 1)

The method of claim 1, wherein the IGF-1R AS ODN is present in the chamber at about 1 μg to about 5 μg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the IGF-1R AS ODN is present at about 2 μg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tumor cells are not exposed to temperatures above body temperature.

### Claim 8 (depends on 1)

The method of claim 1, wherein about 106 tumor cells are present in the chamber.

### Claim 9 (depends on 1)

The method of claim 1, wherein the brain cancer is selected from a grade II astrocytoma, a grade AIII astrocytoma, a grade AIII-G astrocytoma, and a grade IV astrocytoma (glioblastoma multiforme).

### Claim 10

A biodiffusion chamber for implantation into a subject having brain cancer, the biodiffusion chamber comprising:
(a) irradiated tumor cells,
wherein the tumor cells comprise adherent cells obtained from the subject's tumor tissue;
wherein the tumor cells are pre-incubated with insulin-like growth factor receptor-1 antisense oligodeoxynucleotide (IGF-1R AS ODN) prior to encapsulation within the chamber; and
(b) irradiated IGF-1R AS ODN wherein the IGF-1R AS ODN has the sequence of SEQ ID NO:1;
wherein the ratio of tumor cells to IGF-1R AS ODN in the chamber is in a range from about 3.75×105 cells:μg AS ODN to about 6.25×105 cells: μg AS ODN.

### Claim 11 (depends on 10)

The biodiffusion chamber of claim 10, wherein the IGF-1R AS ODN is present at about 1 to about 5 μg.

### Claim 12 (depends on 10)

The biodiffusion chamber of claim 10, wherein the IGF-1R AS ODN is present at about 2 μg.

### Claim 13 (depends on 10)

The biodiffusion chamber of claim 10, wherein the tumor cells in the chamber are enriched for Nestin-positive cells compared to the tumor tissue obtained from the subject.

### Claim 14 (depends on 10)

The biodiffusion chamber of claim 10, wherein about 106 tumor cells are present in the chamber.

### Claim 15 (depends on 10)

The biodiffusion chamber of claim 10, wherein the tumor cells are obtained from the subject using a tissue morselator.

### Claim 16 (depends on 15)

The biodiffusion chamber of claim 15, wherein the tissue morselator comprises a high-speed reciprocating inner cannula within a stationary outer cannula.

### Claim 17 (depends on 15)

The biodiffusion chamber of claim 15, wherein the tissue morselator does not produce heat directed to the tumor tissue when the tissue is obtained from the subject.

### Claim 18 (depends on 10)

The biodiffusion chamber of claim 10, wherein the tumor cells are present in a range from about 750,000 to about 1,250,000 in the chamber.

### Claim 19 (depends on 10)

The biodiffusion chamber of claim 10, wherein the ratio of tumor cells to AS ODN in the chamber is about 5.0×105 cell:μg.

### Claim 20 (depends on 16)

The biodiffusion chamber of claim 16, wherein the outer cannula comprises a side aperture, and further wherein the tumor cells are drawn into the side aperture by electronically controlled variable suction.
